



Rexahn Pharmaceuticals, Inc.
Investor Relations Department
15245 Shady Grove Road, Suite
455
Rockville, MD 20850
United States

Visit IR website [↗](#)
Sign-up for email alerts [↗](#)

AMEX: RNN

Last Trade:	2.23
Trade Time:	8:00 PM ET 05/25/18
Change:	0.07 ↑ (3.241%)
Day Range	2.15 - 2.25
52-Week Range	1.42 - 4.37
Volume	282,664


Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has two clinical stage oncology candidates, RX-3117 and RX-5902 (Supinoxin™), and additional compounds in preclinical development to treat multiple types of cancer.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

05/15/18

[Rexahn Phase 2a Combination Study of RX-3117 and Abraxane® in First-line Metastatic Pancreatic Cancer Patients Advances to Second Stage](#)

05/07/18

[Rexahn Reports First Quarter 2018 Financial Results](#)

04/26/18

[Rexahn to Present Clinical Data at 2018 American Society of Clinical Oncology \(ASCO\) Annual Meeting](#)

03/13/18

[Rexahn Pharmaceuticals to Present at Two Upcoming Conferences](#)

03/12/18

[Rexahn Pharmaceuticals Reports Full Year 2017 Financial Results](#)

Financials [\[View all \]](#)

[First Quarter Financial Results](#)

03/09/18

[Annual Report \(10-K\)](#)

04/23/18

[Proxy Statement \(DEF 14A\)](#)

05/04/18

[Quarterly Report \(10-Q\)](#)

11/03/17

[Quarterly Report \(10-Q\)](#)

08/04/17

[Quarterly Report \(10-Q\)](#)